ADIL Stock Catalyst: Adial Pharmaceuticals Announces Publication of Positive AD04 Trial Data

Apr 9, 2024 · 6:55pm ET

Company highlights safety and compliance in Alcohol Use Disorder treatment study.

Max move

+149.1%

High of day $68.50

Sparker timei

6:55pm ET

ADIL · Apr 9, 2024

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Adial Pharmaceuticals, Inc. (ADIL) announced on April 10, 2024, the publication of a peer-reviewed article detailing promising safety data and high patient compliance from a clinical trial of its AD04 drug candidate for Alcohol Use Disorder.

The published article emphasizes that AD04 demonstrated favorable safety profiles and significantly higher patient compliance rates compared to placebo in the trial.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ADIL sparks.

Download Sniper App →

Catch the next ADIL-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →